期刊文献+

盐酸特比萘芬片治疗真菌性皮肤病的临床分析及安全性观察 被引量:8

Clinical analysis and safety observation of Terbinafin Hydrochloride Tablets in the treatment of mycosis
下载PDF
导出
摘要 目的评价盐酸特比萘芬片治疗真菌性皮肤病的临床疗效和不良反应。方法 360例真菌性皮肤病患者,随机分成3组,分别给予盐酸特比萘芬片口服加外用,伊曲康唑口服,氟康唑口服治疗。结果 3组患者经治疗后,特比萘芬组总有效率明显优于其他2组。结论特比萘芬是治疗皮肤真菌病的有效药物,其远期疗效优于伊曲康唑和氟康唑,值得临床推广应用。 Objective To evaluate the clinical efficacy and adverse reaction in the treatment of mycosis with Terbinafin Hyrochloride Tablets. Methods Three hundred and sixty patients were randomly assigned into 3 groups, oral and external use of Terbinafin H ydrochloride Tablets group,oral administration of itraconazle group,and Fluconazole group. Results After the trial on three dif- ferent groups of patients, the efficiency of Terbinafin Hydrochloride Tablets is evidently better than the others. Conclusion Terbinafin Hydrochloride Tablets were long-term effective and safe in treating mycosis when compared with Itraconazle and Fluconazole. Terbinafin Hydrochloride Tablets is worth of clinical application.
作者 赵月 王辉
出处 《西北药学杂志》 CAS 2013年第4期418-419,共2页 Northwest Pharmaceutical Journal
关键词 盐酸特比萘芬片 真菌性皮肤病 临床分析 安全性 Terbinafin Hydrochloride Tablets mycosis clinical analysis safety
  • 相关文献

参考文献4

  • 1赵辩.临床皮肤病学[M].4版.南京:江苏科学技术出版社,2010:1314-1315.
  • 2Ganzinger U, Stutz A, Petranyi G,et al. Allylamines:topical and treatment of dermatomycoses with a newclass of antifungal agents [J]. Acta Dermatovenereologi-ca,1986,121:121.
  • 3Birnbaum J E. Pharmacology of the allylamines[J]. J AmAcad Dermatol,1990,23 :782.
  • 4刘洪涛,张军东,曹永兵,姜远英.真菌耐药性研究进展[J].中国药学杂志,2003,38(5):328-331. 被引量:39

二级参考文献19

  • 1Stevens DA. Therapy for opportunistic fungal infectious: past,present and future[ J ]. Indian J Cancer, 1995,32 (1) : 1.
  • 2Powderly WG,Keath M, Anderson S, et al. Amphotericin B-resistant Cyptococcus neoformans in a patient with AIDS[J]. Infect Dis Clin Pract , 1990,1 : 314.
  • 3Louie A,Kaw P,Banerjee P, et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endoearditis and pyelonephritis [ J ]. Anti Agents Chem ,2001,45(2) :485.
  • 4Yamaguchi H. Molecular and biochemical mechanisms of drug resistance in fungi [ J ]. Nippon Ishinkin Gakkai Zasshi, 1999,40(4) : 199.
  • 5Kohli A,Smriti,Mukhopadhyay K, et al. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry[J]. Anti Agents Chem,2002,46(4): 1046.
  • 6Loftier J, Einsele H, Hebart H, et al. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains[J]. FEMS Microbiol Lett ,2000,185(1) :59.
  • 7Perea S, Lopez-Robit JL, Kirkpatrick WR, et al. Prevalence of molecular mechanimns of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from HIV-infected patients [ J ]. Anti Agents Chem. 2001.45 (10) : 2676.
  • 8Asai K, Tsuchimori N, Okonogi K, et al. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450[J]. Anti Agents Chem, 1999,43(5) : 1163.
  • 9Edlind TD,Henry KW, Metera KA, et al. Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance[J]. Med Myco1, 2001, 39 ( 3 ) :299.
  • 10Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase(CYP51A1 )from azole-resistant Candida albicans clinical isohtes contribute to resistance to azole antifungal agents [ J ]. Anti Agents and Chemo ,1998,42(2) :241.

共引文献40

同被引文献23

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部